M C Meriggiola
Overview
Explore the profile of M C Meriggiola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Meriggiola M, Jannini E, Lenzi A, Maggi M, Manieri C
Eur J Endocrinol
. 2010 Feb;
162(5):831-3.
PMID: 20150325
The treatment of transsexual subjects is a challenging task for the endocrinologist who, in collaboration with the mental health professional and the surgeon, is called upon to confirm the diagnosis...
12.
Godano A, Maggi M, Jannini E, Meriggiola M, Ghigo E, Todarello O, et al.
J Endocrinol Invest
. 2010 Jan;
32(10):857-64.
PMID: 20065624
No abstract available.
13.
Ghi T, Contro E, Martina T, Piva M, Morandi R, Orsini L, et al.
Ultrasound Obstet Gynecol
. 2009 Jan;
33(2):209-12.
PMID: 19173235
Objective: To evaluate if cervical length predicts prepartum bleeding and emergency Cesarean section in cases of placenta previa. Methods: Between September 2005 and September 2007, cervical length was measured by...
14.
Ghi T, Giunchi S, Kuleva M, Santini D, Savelli L, Formelli G, et al.
Ultrasound Obstet Gynecol
. 2007 Sep;
30(5):778-82.
PMID: 17899576
Objective: To evaluate the feasibility of three-dimensional multiplanar sonography in the local staging of cervical carcinoma. Methods: Between January 2005 and May 2006, 14 patients with invasive cervical carcinoma underwent...
15.
Costantino A, Cerpolini S, Perrone A, Ghi T, Pelusi C, Pelusi G, et al.
Minerva Ginecol
. 2007 Jun;
59(3):299-310.
PMID: 17576406
Contraception is a crucial human right for its role on health, development and quality of life. Since the introduction of hormonal female contraception the burden of family planning has fallen...
16.
Gambineri A, Pagotto U, De Lasio R, Meriggiola M, Costantino A, Patton L, et al.
J Endocrinol Invest
. 2005 Jun;
28(3):241-6.
PMID: 15952409
The aim of this study was to evaluate the effect of selective and short-term sex hormone modifications on ghrelin levels in normal-weight eugonadal men undergoing hormonal contraceptive treatments. Seven men...
17.
Meriggiola M, Costantino A, Saad F, DEmidio L, Morselli Labate A, Bertaccini A, et al.
J Clin Endocrinol Metab
. 2005 Jan;
90(4):2005-14.
PMID: 15634716
The goal of this study was to find the most favorable injection interval of norethisterone enanthate (NETE) plus testosterone undecanoate (TU) in terms of gonadotropin, sperm suppression, and prostatic effects....
18.
Meriggiola M, Costantino A, Cerpolini S, Bremner W, Huebler D, Morselli-Labate A, et al.
J Clin Endocrinol Metab
. 2003 Dec;
88(12):5818-26.
PMID: 14671175
In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose cyproterone acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU....
19.
Meriggiola M, Costantino A, Cerpolini S
Contraception
. 2002 May;
65(4):269-72.
PMID: 12020775
Hormones inhibit fertility in men by suppressing sperm production. Testosterone-enanthate induced azoospermia has proven to provide optimal contraceptive protection. Preliminary studies have shown that testosterone alone or androgen-progestin combinations induce...
20.
Meriggiola M, Bremner W, Costantino A, DI Cintio G, Flamigni C
Hum Reprod
. 1998 Jul;
13(5):1225-9.
PMID: 9647551
After a control phase, 10 normal men received cyproterone acetate (CPA) at a dose of 25 mg/day (CPA-25; n=5) or 12.5 mg/day (CPA-12.5; n=5) plus testosterone enanthate (TE) 100 mg/week,...